These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 27761468)

  • 21. Emerging drugs for diabetic macular edema.
    Schwartz SG; Flynn HW; Scott IU
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):397-405. PubMed ID: 25141904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography.
    Bandyopadhyay S; Bandyopadhyay SK; Saha M; Sinha A
    Int Ophthalmol; 2018 Feb; 38(1):241-249. PubMed ID: 28160192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema.
    Matsuda S; Tam T; Singh RP; Kaiser PK; Petkovsek D; Carneiro G; Zanella MT; Ehlers JP
    J Diabetes Complications; 2014; 28(2):166-70. PubMed ID: 24374138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.
    Moshfeghi DM; Kaiser PK; Michels S; Midena E; Kitchens JW; Prenner JL; Regillo CD; Reichel E
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6 Suppl):S4-S14. PubMed ID: 27348433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema.
    Zhang X; Wang N; Schachat AP; Bao S; Gillies MC
    Curr Mol Med; 2014 Mar; 14(3):376-84. PubMed ID: 24467200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aqueous Humor Levels of Soluble Vascular Endothelial Growth Factor Receptor and Inflammatory Factors in Diabetic Macular Edema.
    Noma H; Mimura T; Yasuda K; Motohashi R; Kotake O; Shimura M
    Ophthalmologica; 2017; 238(1-2):81-88. PubMed ID: 28564655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process.
    Ehrlich R; Harris A; Ciulla TA; Kheradiya N; Winston DM; Wirostko B
    Acta Ophthalmol; 2010 May; 88(3):279-91. PubMed ID: 20222885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-VEGF Therapy for Diabetic Eye Diseases.
    Bahrami B; Hong T; Gilles MC; Chang A
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):535-545. PubMed ID: 29076303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial growth factor and diabetic macular edema.
    Lally DR; Shah CP; Heier JS
    Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability.
    Peters S; Cree IA; Alexander R; Turowski P; Ockrim Z; Patel J; Boyd SR; Joussen AM; Ziemssen F; Hykin PG; Moss SE
    Cytokine; 2007 Nov; 40(2):144-50. PubMed ID: 17959386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema.
    Lee H; Jang H; Choi YA; Kim HC; Chung H
    Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):715-721. PubMed ID: 29392317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein E2 and E3, but Not E4, Promote Retinal Pathologic Neovascularization.
    Masuda T; Shimazawa M; Hashimoto Y; Kojima A; Nakamura S; Suemori S; Mochizuki K; Kawakami H; Kawase K; Hara H
    Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1208-1217. PubMed ID: 28241308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concentration of acute phase factors in vitreous fluid in diabetic macular edema.
    Kimura K; Orita T; Kobayashi Y; Matsuyama S; Fujimoto K; Yamauchi K
    Jpn J Ophthalmol; 2017 Nov; 61(6):479-483. PubMed ID: 28755024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration.
    Strain WD; Cos X; Prünte C
    Diabetes Res Clin Pract; 2017 Apr; 126():1-9. PubMed ID: 28189948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.
    Funatsu H; Yamashita H; Ikeda T; Mimura T; Eguchi S; Hori S
    Ophthalmology; 2003 Sep; 110(9):1690-6. PubMed ID: 13129863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders.
    Funatsu H; Yamashita H; Ikeda T; Nakanishi Y; Kitano S; Hori S
    Am J Ophthalmol; 2002 Apr; 133(4):537-43. PubMed ID: 11931788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema.
    Owen LA; Hartnett ME
    Curr Diab Rep; 2013 Aug; 13(4):476-80. PubMed ID: 23649946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.